TIOtropium safety and performance In Respimat® (TIOSPIRTM): analysis of asian cohort of COPD patients.
![Thumbnail](/bitstream/handle/20.500.14353/541/PUB-JAR-M-2016-Zhong-FLT.pdf.jpg?sequence=5&isAllowed=y)
View/ Open
Date
2016-08-04Author
MeSH term
Pulmonary Disease, Chronic Obstructive![MeSH MeSH](/themes/Mirage2/images/MeSH-logo.jpg)
Treatment Outcome
![MeSH MeSH](/themes/Mirage2/images/MeSH-logo.jpg)
Tiotropium Bromide
![MeSH MeSH](/themes/Mirage2/images/MeSH-logo.jpg)
Bronchodilator Agents
![MeSH MeSH](/themes/Mirage2/images/MeSH-logo.jpg)
Metadata
Show full item record
Share
Abstract
The TIOtropium Safety and Performance In Respimat (TIOSPIR) trial showed similar safety and exacerbation efficacy profiles for tiotropium Respimat and HandiHaler in patients with COPD. The TIOSPIR results for patients in Asia are presented here. Methods: TIOSPIR evaluated once-daily tiotropium Respimat 5 and 2.5 µg with HandiHaler 18 µg in patients with COPD. Primary endpoints included time to death and time to first COPD exacerbation. Safety and exacerbation efficacy profiles were determined for the Asian region, and for Asia (all treatment arms pooled) versus the rest of the world (RoW). Results: In Asia (n = 2356), time to death was similar for Respimat 5 and 2.5 µg versus HandiHaler 18 µg (hazard ratio (HR) (95% CI): 0.96 (0.67, 1.38) and 1.23 (0.87, 1.73)). Risk of COPD exacerbation was similar for Respimat 5 µg, but increased for 2.5 µg versus HandiHaler 18 µg (HR (95% CI): 0.99 (0.85, 1.15) and 1.17 (1.00, 1.35)). Time to death in Asia and RoW was similar (HR (95% CI): 1.15 (0.99, 1.35)). Time to first COPD exacerbation was longer (HR (95% CI): 0.84 (0.78, 0.89)) and exacerbation rates were lower in Asia, but severe exacerbations were more frequent than in the RoW. Risk of major adverse cardiovascular events was similar for both regions. Conclusion: Similar safety and exacerbation efficacy profiles were observed for tiotropium Respimat 5 µg and HandiHaler 18 µg in patients with COPD from Asia, analogous to the global analysis. Asian patients had lower risk of, and fewer exacerbations overall, but a higher proportion of severe exacerbations than in the RoW.
Recommended Citation
Zhong, N., Moon, H. S., Lee, K. H., Mahayiddin, A. A., Boonsawat, , Isidro, M. G., ... & Anzueto, A. (2016). TIOtropium safety and performance In Respimat® (TIOSPIRTM): analysis of asian cohort of COPD patients.Type
ArticleISSN
13237799Keywords
TIOtropium Safety and Performance In Respimat Exacerbation TIOtropium Safety and Performance In Respimat Tiotropium Respimat 5 μg Tiotropium HandiHaler 18 μg Chronic obstructive lung disease Morality Health-related quality of life Exacerbation efficacy profile Chronic obstructive pulmonary disease Clinical respiratory medicine
Subject
Collections
Related items
Showing items related by title, author, creator and subject.
-
Cross-sectional survey on the knowledge, attitude and practice of male Filipino seafarers on sexual health.
Guevara, N.; Pineda, M.
; Dorotan, M.
; Ghimire, K.; Co, M.; Guzman, K.; Postrano, L. (Via Medica Journals, 2010)
The Philippines is currently the world’s leading supplier of seafarers aboard foreign vessels, accounting for nearly a quarter of the world’s maritime industry. Seafarers, being mobile, have a significant contribution ... -
Multi-country study on the prevalence and clinical features of peripheral arterial disease in Asian type 2 diabetes patients at high risk of atherosclerosis
Rhee, Sang Youl; Guan, Heng; Liu, Zhi-Min
; Cheng, Stephen Wing Keung
; Waspadji, Sarwono; Palmes, Patricio
; Tai, Tong Yuan; Suwanwalaikorn, Sompongse
; Kim, Young Seol (Elsevier, 2007-04-01)
Objective: PAD-SEARCH was the first international study to investigate the prevalence of peripheral arterial disease (PAD) in Asian type 2 diabetic patients and to demonstrate the relationships between putative risk ... -
Durability of the beneficial effect of MLC601 (NeuroAiD™) on functional recovery among stroke patients from the Philippines in the CHIMES and CHIMES-E studies
Navarro, Jose C.; Chen, Cristopher LH.; Lee, Chun F.; Herminigildo, Gan H.; Lao, Annabelle Y.; Venketasubramanian, Narayanaswamy; Baroque, Alejandro II C.; Hiyadan, John Harold B.; Chua, Carlos L.; San Jose, Ma Cristina; Advincula, Joel M.; Venketasubramanian, Narayanaswamy; CHIMES-E Study Investigators (SAGE Publications Inc., 2017-04)Background and Aim: A pre-specified country analysis of subjects from the Philippines in the CHInese Medicine NeuroAiD Efficacy on Stroke recovery (CHIMES) Study showed significantly improved functional and neurological ...